Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Summit Therapeutics Provides Update on Ridinilazole
Details : SMT19969 (ridinilazole) is a targeted-spectrum antimicrobial that shows potential in treatment of initial C difficile infection and in providing sustained benefit through reduction in disease recurrence.
Brand Name : SMT19969
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 14, 2022
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ridinilazole is the investigational first-in-class drug that completed enrollment of a Phase III clinical trial, Ri-CoDIFy. The primary endpoint of this trial seeks to demonstrate the superiority of ridinilazole in sustained clinical response as compared...
Brand Name : SMT19969
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2021
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ridinilazole is our investigational drug currently in Phase III Ri-CoDIFy clinical trials with the goal of use as first-line therapy to treat initial infection and reduce recurrence of Clostridioides difficile infection.
Brand Name : SMT19969
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2021
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Polar Capital
Deal Size : $50.0 million
Deal Type : Private Placement
Summit Announces Closing of Private Placement of $50 Million
Details : Funds to be used for continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole; Preparatory activities to support the commercial launch of ridinilazole; Development of early-stage research projects using Discuva Platfo...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 06, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Polar Capital
Deal Size : $50.0 million
Deal Type : Private Placement
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing
Summit Announces Agreement For a Fundraising of Approximately $50 Million
Details : Funds support continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole for the treatment of Clostridium difficile infection; launch of Ridinilazole and Development of early-stage research projects using the Company’...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
Details : The data demonstrated that ridinilazole’s microbiome preservation resulted in a gut environment expected to inhibit the growth of C. difficile. In contrast, vancomycin treatment resulted in a gut environment that may more highly favor the growth of C. ...
Brand Name : SMT19969
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 13, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Eurofarma Laboratorios S.A
Deal Size : $3.8 million
Deal Type : Collaboration
Summit Therapeutics to Receive $1.0 Million Milestone Payment
Details : The milestone payment was initiated by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 06, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Eurofarma Laboratorios S.A
Deal Size : $3.8 million
Deal Type : Collaboration
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : $72.5 million
Deal Type : Funding
Details : The additional funding is being provided to support a new clinical trial in adolescent patients and brings the total value of the award to up to $72.5 million.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : $72.5 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?